Under the terms of the agreement, HeartBeam and Samsung will find and define opportunities for collaboration, tapping the former’s expertise and patented technology
HeartBeam and Samsung intend to use each other’s expertise to improve cardiac diagnostic capabilities. (Credit: Stephen Andrews on Unsplash)
Cardiac technology company HeartBeam has signed a strategic alliance agreement (SAA) with Samsung for the assessment and monitoring of cardiac symptoms.
The agreement extends the present SAA between LIVMOR, whose assets HeartBeam acquired in 2022, and Samsung.
Under the terms of the agreement, HeartBeam and Samsung will find and define opportunities for collaboration, tapping the former’s expertise and patented technology.
HeartBeam has designed the first and only 3D-vector electrocardiogram (VECG) platform that enables patients and their clinicians to assess cardiac symptoms quickly and easily in a home setting.
HeartBeam CEO and founder Branislav Vajdic said: “The goal of this partnership is to bring the standard of care for cardiac diagnostic capabilities to patients by utilizing cutting-edge technologies of both Samsung and HeartBeam.
“Our newly acquired state-of-the-art, FDA-cleared, Samsung watch-based arrhythmia detection tool, once integrated with the HeartBeam AIMIGo telehealth platform, presents a unique opportunity to extend our product capabilities well beyond what is currently available for cardiac patients outside of a medical setting.”
LIVMOR, established in 2016, has developed the Halo Atrial Fibrillation (AF) Detection System. It is said to be the world’s first US Food and Drug Administration (FDA)-cleared prescription wearable for continuous cardiac rhythm monitoring.
According to the cardiac technology company, the Halo system offers continuous pulse rhythm monitoring for the on-demand daytime and automatic nighttime identification of AF.
Under the previous SAA, LIVMOR and Samsung created a fully integrated patient care platform that offers prolonged monitoring of a patient’s cardiovascular health in almost any setting.
Samsung Electronics America Federal Healthcare senior director Kevin Jones said: “The strategic collaboration between Samsung and LIVMOR was very successful, resulting in an FDA-cleared solution for Atrial Fibrillation detection centred around the Samsung Galaxy watch and tablet running Samsung’s defence-grade cyber-security system, Knox.”
Both parties may collaborate with the Department of Veterans Affairs via its Accelerating VA Innovation and Learning (AVAIL) programme.
The VA revealed in September that 17 companies have been selected for a potential $650m, five-year programme to develop, test and scale up platforms, services, and care models for the Veterans Health Administration.